Advanced prostate cancer treatment decisions increasingly depend on accurately measuring whether therapies are working, yet newer imaging technologies may paint a different picture than doctors expect. The stakes are high for men with metastatic castration-resistant prostate cancer, where treatment options are limited and timing is critical.
A head-to-head comparison of imaging approaches in 34 patients revealed striking differences in apparent treatment success rates. While conventional CT and bone scans using established PCWG3 criteria identified 23.5% of patients as non-progressing at 12 weeks, the newer PSMA PET technology showed dramatically lower rates—just 8.8% using aPERCIST criteria and 17.6% with PPP criteria. The RECIP-1.0 PSMA-based method matched conventional imaging at 23.5% but demonstrated superior consistency between different radiologists interpreting the scans.
This divergence reflects PSMA PET's heightened sensitivity to detect prostate cancer cells, potentially revealing disease activity that conventional imaging misses. However, greater sensitivity doesn't automatically translate to better patient outcomes. The conventional PCWG3 approach remained the strongest predictor of overall survival, with non-progressing patients living significantly longer. None of the PSMA-based criteria showed meaningful survival correlations.
These findings highlight a critical challenge in precision oncology: more sensitive detection tools can paradoxically complicate treatment decisions. For clinicians managing advanced prostate cancer, this study suggests that while PSMA PET provides valuable diagnostic information, the established imaging criteria may still offer the most reliable framework for determining treatment effectiveness. The technology's true value may lie in initial staging rather than monitoring therapeutic response, pending larger validation studies.